Clinical Trials Browser

Phase 1 × HLX07 × Clear all

NCT05360368 2022-05-05

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Phase 1 Unknown

Other solid neoplasm

Solid Tumor

NCT02648490 2019-07-30

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Phase 1 Completed

Neoplasm Metastasis